Library / Laws / 118th Congress / Senate Bills / S. 142

S. 142

To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.

Senate · 2 versions on the shelf